ePrints

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Lookup NU author(s): Professor Graham Jackson

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Abstract

© 2018 The Author(s) During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

Publication metadata

Author(s): Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos M-V, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Blade J, Sonneveld P

Publication type: Article

Publication status: Published

Journal: Leukemia

Year: 2018

Volume: 32

Issue: 7

Pages: 1542-1560

Print publication date: 01/07/2018

Online publication date: 02/05/2018

Acceptance date: 30/11/2017

Date deposited: 04/06/2018

ISSN (print): 0887-6924

ISSN (electronic): 1476-5551

Publisher: Nature Publishing Group

URL: https://doi.org/10.1038/s41375-018-0040-1

DOI: 10.1038/s41375-018-0040-1

Altmetrics

Share